Clinical trials: Pituitary Dwarfism
Growth Hormone Deficiency
Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm
To estimate the evolution of height and growth rate over 5 years of growth hormone (GH) treatment To estimate the prognostic factors of growth rate with GH treatment To confirm the good clinical and biological safety of GH…
- Trial name
- NCT00163189
- Testing
- Somatropin
- Where
- 19 sites in France
- Volunteers
- 98 people
- Sponsor
- Pfizer
GHD
A Study to Investigate the Safety and Efficacy of Once-weekly PEG-somatropin (GenSci004) in Children With Growth Hormone Deficiency
The purpose of this Phase 3 study is to evaluate the safety and efficacy of once-weekly GenSci004 over 108 weeks in children with GHD aged from 6 months to 17 years old, inclusive.
- Trial name
- ESCALATE (NCT06024967)
- Testing
- PEG-somatropin
- Volunteers
- 180 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Growth Hormone Disorders
A Post Marketing Surveillance Study for NutropinAq® in Adults With Growth Hormone Deficiency
This study is a multicenter, open-label, observational, post marketing surveillance program to collect information on the use of NutropinAq® in adults suffering from Growth Hormone Deficiency in Germany, Italy, and United Kingdom
- Trial name
- NCT00455884
- Where
- United Kingdom
- Volunteers
- 546 people
- Sponsor
- Ipsen
Growth Disorder, Growth Hormone Deficiency in Children
Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)
This study is conducted in Europe and the United States of America (USA). The aim of the study is to validate two measures for growth hormone deficiency in children, the Treatment Related Impact Measure of Childhood Growth…
- Trial name
- NCT02580032
- Testing
- No treatment given
- Where
- 28 sites in United States, United Kingdom
- Volunteers
- 252 people
- Sponsor
- Novo Nordisk A/S
Growth Hormone Deficiency
A Study of Zomacton in Children With Growth Hormone Deficiency
This trial is set up to compare Zomacton to Genotropin for the treatment of growth hormone deficiency in children. The children will be treated for 1 year.
- Trial name
- NCT00884000
- Testing
- Genotropin, Zomacton
- Where
- 43 sites in Hungary, India and 5 more
- Volunteers
- 165 people
- Sponsor
- Ferring Pharmaceuticals
Growth Hormone Deficiency, Idiopathic Short Stature
Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature
This study evaluates long-term safety and effectiveness of Growtropin®-II treatment in children with short stature.
- Conditions
- Growth Hormone Deficiency, Idiopathic Short Stature, Turner Syndrome, Small for Gestational Age
- Trial name
- NCT04798690
- Where
- South Korea
- Volunteers
- 5,000 people
- Sponsor
- Dong-A ST Co., Ltd.
Growth Hormone Deficiency, Turner Syndrome
Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector
This is an international, multicenter study involving children treated with Saizen®, a growth hormone, who will be trained to use easypod, a new electronic injector and will complete a questionnaire after 12 week of use.
- Conditions
- Growth Hormone Deficiency, Turner Syndrome, Chronic Renal Failure, Small for Gestational Age
- Trial name
- NCT00738205
- Volunteers
- 834 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Growth Hormone Deficiency
Surveillance of Treatment of Children With Growth Hormone Deficiency With Zomacton®
The purpose of this study is to investigate the long-term treatment with Zomacton® for pituitary short stature in children with insufficient growth hormone production and/or short stature caused by Turner's syndrome.
- Trial name
- NCT01731028
- Testing
- Somatropin
- Sponsor
- Ferring Pharmaceuticals
Growth Hormone Deficiency
Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)
This study assesses the safety and tolerability of weekly TV-1106 compared to daily rhGH in adults with GHD who have previously been treated with rhGH.
- Trial name
- NCT02410356
- Testing
- TV-1106, dGH
- Where
- 50 sites in United States, Austria and 6 more
- Volunteers
- 34 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Growth Hormone Deficiency
Study of TV-1106 in Growth Hormone-Deficient Adults
The primary objective of this study is to determine the efficacy of 6 months of treatment with TV-1106 compared with placebo on body fat composition.
- Trial name
- NCT02410343
- Testing
- TV-1106
- Where
- 33 sites in United States, Austria and 5 more
- Volunteers
- 14 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Pediatric Growth Hormone Deficiency
A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD)
This is a two-part clinical study for children with growth hormone deficiency. In the first part, participants will be randomly assigned to receive different doses of an oral treatment (GS3-007a dry suspension) or a placebo for…
- Trial name
- NCT07264595
- Testing
- GS3-007a dry suspension, rhGH injection
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Pediatric Growth Hormone Deficiency (PGHD)
A Bioequivalence Study of Two Different PEG-rhGH Preparations.
The purpose of this study is to investigate whether PEG-rhGH with new preparation is bioequivalent to PEG-rhGH with present preparation.
- Trial name
- NCT06331026
- Testing
- PEG-rhGH with new preparation (T), PEG-rhGH with present preparation (R)
- Where
- China
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Growth Hormone Disorder, Adult Growth Hormone Deficiency
Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)
This trial is conducted in Japan. To investigate the long-term efficacy as assessed by change in fat mass and safety after 48 weeks of treatment of Growth Hormone in adults with Growth Hormone Deficiency, comparing two different…
- Trial name
- NCT00184743
- Testing
- somatropin
- Where
- Japan
- Volunteers
- 112 people
- Sponsor
- Novo Nordisk A/S
Growth Hormone Deficiency
Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency
The primary objective of this study is to evaluate the clinical effect of TV-1106.
- Trial name
- NCT01811576
- Testing
- TV-1106, Recombinant human growth hormone
- Where
- 23 sites in United States, Czechia and 7 more
- Volunteers
- 52 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Growth Hormone Deficiency (GHD)
Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study
To assess the immunogenicity of Saizen® solution for injection in adult subjects with documented Growth Hormone Deficiency (GHD).
- Trial name
- NCT01237340
- Testing
- Saizen®
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- EMD Serono
Growth Hormone Deficiency
Phase 1 Safety Study of ALRN-5281 in Healthy Subjects
The primary objective of this study is to evaluate the safety and tolerability of a single dose of ALRN-5281 administered by subcutaneous injection to healthy adult volunteers.
- Trial name
- NCT01775358
- Testing
- ALRN-5281 0.015 mg/kg, ALRN-5281 0.05 mg/kg, ALRN-5281 0.15 mg/kg
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Aileron Therapeutics, Inc.
Short Stature, Idiopathic, Infant, Small for Gestational Age
Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.
The purpose of this study is to assess the ease of use, preference, and safety after 8 weeks subcutaneous administration of EutropinPen Inj. in patients pretreated with recombinant human growth hormone by reusable device.
- Conditions
- Short Stature, Idiopathic, Infant, Small for Gestational Age, Growth Hormone Deficiency, Chronic Renal Failure
- Trial name
- NCT03015909
- Testing
- Somatropin
- Where
- South Korea
- Volunteers
- 116 people
- Sponsor
- LG Life Sciences
Growth Hormone Deficiency
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.
- Trial name
- SkyPASS (NCT05775523)
- Testing
- No intervention
- Where
- 27 sites in United States
- Volunteers
- 500 people
- Sponsor
- Ascendis Pharma Endocrinology Division A/S
Pediatric Growth Hormone Deficiency
Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
This is an open-label, randomized, multicenter, efficacy and safety study of weekly MOD-4023 compared to daily Genotropin therapy in pre-pubertal children with growth hormone deficiency.
- Trial name
- NCT02968004
- Testing
- MOD-4023, Somatropin
- Where
- 81 sites in United States, Argentina and 18 more
- Volunteers
- 224 people
- Sponsor
- OPKO Health, Inc.
Growth Hormone Disorder, Adult Growth Hormone Deficiency
Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083
This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of NNC126-0083 in growth hormone deficient adults
- Trial name
- NCT00715689
- Testing
- NNC126-0083
- Where
- 3 sites in Denmark
- Volunteers
- 33 people
- Sponsor
- Novo Nordisk A/S